Company: LHI
Filing Date: 2025-02-14
Form Type: DRS/A
Source: 0001213900-25-014190
Chunk: 257

Company: Living Homeopathy International Ltd.
Filing Date: 2025-02-14
Form: DRS/A
Chunk 257
---
 measurement of a tax position taken (or expected to be taken) in a tax return. It also
provides guidance on the recognition of income tax assets and liabilities, classification accounting for interest and penalties associated
with tax positions, years open for tax examination, accounting for income taxes in interim periods and income tax disclosures. There were
no material uncertain tax positions as of March 31, 2024 and 2023.

The Company identifies related parties, accounts
for, and discloses related party transactions in accordance with ASC 850, “Related Party Disclosures” and other relevant ASC
standards.

The Company presents comprehensive income in accordance
with ASC Topic 220, Comprehensive Income, (“ASC 220”). ASC 220 states that all items that are required to be recognized under
accounting standards as components of comprehensive income be reported in the consolidated financial statements. Total comprehensive income
consists of two components, net income and other comprehensive income. Other comprehensive income refers to revenue, expenses, gains and
losses that are recorded as an element of shareholders’ equity but are excluded from net income. Other comprehensive income consists
of a foreign currency translation adjustment resulting from the Company’s subsidies not using the US$ as the Company’s functional
currency.

In the normal course of business, the Company
is subject to contingencies, including legal proceedings and claims arising out of the business that relate to a wide range of matters,
such as government investigations and tax matters. The Company recognizes its liability for such contingency if it determines it is probable
that a loss has occurred, and a reasonable estimate of the loss can be made. The Company may consider many factors in making these assessments
including historical and the specific facts and circumstances of each matter. Based on currently available information, the Company does
not believe that the ultimate outcome of any unresolved matters, individually and in the aggregate, is reasonably possible to have a material
adverse effect on the financial position, results of operations or cash flows.

The Company computes earnings per share in accordance
with ASC 260, “Earnings per Share”. ASC 260 requires companies with complex capital structures to present basic and diluted
EPS. Basic EPS is measured as net income divided by the weighted average number of ordinary shares outstanding for the period. Diluted
presents the dilutive effect on a per share basis of potential ordinary shares (e.g., convertible securities, options and warrants) as
if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential